MedicarePartD.guide

A non-government resource built from CMS public data

IL-17, IL-23 and IL-12/23 biologics on every 2026 Virgin Islands Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 1 stand-alone Part D plans in Virgin Islands cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
IL-17, IL-23 and IL-12/23 biologics by 2026 Virgin Islands Part D plan
DrugAARP Medicare Rx Preferred from UHC$114.80/moS5820-038
StelaraustekinumabNot covered
ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and othersNot covered
Wezlanaustekinumab-auubNot covered
Selarsdiustekinumab-aeknNot covered
SkyrizirisankizumabTier 5PA25%QL 1/28d
TremfyaguselkumabTier 5PA25%
CosentyxsecukinumabTier 5PA25%QL 10/30d
TaltzixekizumabNot covered
BimzelxbimekizumabNot covered

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.